北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)
作者: Mrozek, E.1,2; Kolesar, J.3; Young, D.4; Allen, J.2,5; Villalona-Calero, M.1; Shapiro, C. L.1,2
关键词: breast cancer ; irinotecan ; mitomycin ; topoisomerase I
刊名: ANNALS OF ONCOLOGY
发表日期: 2008-08-01
DOI: 10.1093/annonc/mdn154
卷: 19, 期:8, 页:1417-1422
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: COLON-CARCINOMA CELLS ; NQO1 GENE-EXPRESSION ; DT-DIAPHORASE ; PLUS VINBLASTINE ; ANTHRACYCLINE ; TAXANE ; CAPECITABINE ; DOCETAXEL ; VINORELBINE ; COMBINATION
英文摘要:

Background: Preclinical studies show that mitomycin-C (MMC) followed by irinotecan (CPT-11) is synergistic. Therefore, we evaluated the toxicity and efficacy of sequentially administered low-dose MMC and CPT-11 in patients (pts) with pretreated metastatic breast cancer (MBC). Secondary objective was to evaluate the correlation between MMC-induced topoisomerase I (TOPO I) expression and NAD(P)H:quinone oxireductase 1 (NQO1) genotypes in peripheral blood mononuclear cells (PBMC) and efficacy or toxicity of the regimen.

Design: Thirty-two pts received MMC i.v. 6 mg/m(2) day 1 and CPT-11 i.v. 125 mg/m(2) days 2 and 8 every 28 days for maximum of six cycles. TOPO I expression and NQO1 reductase genotyping in 23 of 32 (72%) pts were assayed by PCR.

Results: The median time to progression (TTP) was 4.7 months (95% confidence interval 4.0-5.4 months). TOPO I expression was increased 5- to 10-fold and 20- to 30-fold in PBMC at 24 and 168 h, respectively. There was no relationship between these markers and efficacy or toxicity of the regimen.

Conclusions: Sequential low-dose MMC and CPT-11 was active and tolerable by pretreated MBC pts. Future trials should focus on less pretreated MBC pts and sequential tumor biopsies to test the hypothesis that increased intratumoral expression of TOPO I is related to efficacy.

语种: 英语
WOS记录号: WOS:000258136800009
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/63587
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100871, Peoples R China
2.Ohio State Univ, Med Ctr, Arthur G James Canc Hosp, Comprehens Breast Hlth Serv, Columbus, OH 43210 USA
3.Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA
4.Ohio State Univ, Ctr Comprehens Canc, Ctr Biostat, Columbus, OH 43210 USA
5.Ohio State Univ, Med Ctr, Ctr Comprehens Canc, Clin Trials Off, Columbus, OH 43210 USA

Recommended Citation:
Mrozek, E.,Kolesar, J.,Young, D.,et al. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)[J]. ANNALS OF ONCOLOGY,2008,19(8):1417-1422.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Mrozek, E.]'s Articles
[Kolesar, J.]'s Articles
[Young, D.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Mrozek, E.]‘s Articles
[Kolesar, J.]‘s Articles
[Young, D.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2018  北京大学医学部 - Feedback
Powered by CSpace